Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

126 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors.
Bali P, Pranpat M, Bradner J, Balasis M, Fiskus W, Guo F, Rocha K, Kumaraswamy S, Boyapalle S, Atadja P, Seto E, Bhalla K. Bali P, et al. Among authors: atadja p. J Biol Chem. 2005 Jul 22;280(29):26729-34. doi: 10.1074/jbc.C500186200. Epub 2005 Jun 2. J Biol Chem. 2005. PMID: 15937340 Free article.
Cotreatment with histone deacetylase inhibitor LAQ824 enhances Apo-2L/tumor necrosis factor-related apoptosis inducing ligand-induced death inducing signaling complex activity and apoptosis of human acute leukemia cells.
Guo F, Sigua C, Tao J, Bali P, George P, Li Y, Wittmann S, Moscinski L, Atadja P, Bhalla K. Guo F, et al. Among authors: atadja p. Cancer Res. 2004 Apr 1;64(7):2580-9. doi: 10.1158/0008-5472.can-03-2629. Cancer Res. 2004. PMID: 15059915
Superior activity of the combination of histone deacetylase inhibitor LAQ824 and the FLT-3 kinase inhibitor PKC412 against human acute myelogenous leukemia cells with mutant FLT-3.
Bali P, George P, Cohen P, Tao J, Guo F, Sigua C, Vishvanath A, Scuto A, Annavarapu S, Fiskus W, Moscinski L, Atadja P, Bhalla K. Bali P, et al. Among authors: atadja p. Clin Cancer Res. 2004 Aug 1;10(15):4991-7. doi: 10.1158/1078-0432.CCR-04-0210. Clin Cancer Res. 2004. PMID: 15297399
Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3.
George P, Bali P, Annavarapu S, Scuto A, Fiskus W, Guo F, Sigua C, Sondarva G, Moscinski L, Atadja P, Bhalla K. George P, et al. Among authors: atadja p. Blood. 2005 Feb 15;105(4):1768-76. doi: 10.1182/blood-2004-09-3413. Epub 2004 Oct 28. Blood. 2005. PMID: 15514006 Free article.
Hydroxamic acid analogue histone deacetylase inhibitors attenuate estrogen receptor-alpha levels and transcriptional activity: a result of hyperacetylation and inhibition of chaperone function of heat shock protein 90.
Fiskus W, Ren Y, Mohapatra A, Bali P, Mandawat A, Rao R, Herger B, Yang Y, Atadja P, Wu J, Bhalla K. Fiskus W, et al. Among authors: atadja p. Clin Cancer Res. 2007 Aug 15;13(16):4882-90. doi: 10.1158/1078-0432.CCR-06-3093. Clin Cancer Res. 2007. PMID: 17699868
Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells.
Nimmanapalli R, Fuino L, Bali P, Gasparetto M, Glozak M, Tao J, Moscinski L, Smith C, Wu J, Jove R, Atadja P, Bhalla K. Nimmanapalli R, et al. Among authors: atadja p. Cancer Res. 2003 Aug 15;63(16):5126-35. Cancer Res. 2003. PMID: 12941844
126 results